M&A

29 November, 2009

UPDATE 1-Takeda: eyeing M&A for generics in emerging markets

* Takeda head: eyeing M&A for generic biz in emerging markets

* Company is focusing on South America market

* Takeda head: not interested in Japan generic drug market

TOKYO, Nov 30 (Reuters) - Japan's biggest drugmaker, Takeda Pharmaceutical (4502.T), could acquire a company to help it enter the generic drug business in emerging markets, with a particular focus on South America, its president said on Monday.

Yasuchika Hasegawa, speaking after a speech on Japanese corporate management practices, also said the company was not interested in entering the generic business in Japan.

When asked what emerging markets Takeda might target, Hasegawa said the company was focused on South America.

He did not elaborate on potential targets. (Reporting by Nathan Layne; Editing by Edwina Gibbs) ((nathan.layne@thomsonreuters.com; +813-6441-1801; Reuters Messaging: nathan.layne.reuters.com@reuters.net)) ((If you have a query or comment on this story, send an email to news.feedback.asia@thomsonreuters.com))

Source: http://www.reuters.com